1月13日,诺瓦瓦克斯医药盘中大涨超8%。最近的财报数据显示,该股实现营业收入70.45百万美元,净利润-2.02亿美元,每股收益-1.25美元,毛利50.65百万美元,市盈率3.79倍。机构评级方面,在所有10家参与评级的机构中,50%的券商给予买入建议,20%的券商给予持有建议,30%的券商给予卖出建议。诺瓦瓦克斯医药公司简介:诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。该公司处于临床...
Source Link1月13日,诺瓦瓦克斯医药盘中大涨超8%。最近的财报数据显示,该股实现营业收入70.45百万美元,净利润-2.02亿美元,每股收益-1.25美元,毛利50.65百万美元,市盈率3.79倍。机构评级方面,在所有10家参与评级的机构中,50%的券商给予买入建议,20%的券商给予持有建议,30%的券商给予卖出建议。诺瓦瓦克斯医药公司简介:诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。该公司处于临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.